Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study

RCT (n=660) found that delafloxacin was non-inferior to vancomycin and aztreonam combination therapy for objective response (78.2% vs 80.9%) and clinical cure (52.0% vs 50.5%). Treatment emergent adverse effects were less frequent with delafloxacin (0.9% vs 4.3%).